Skip to main content

Table 2 CTCs detected in patient samples

From: Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients

  CTC subtype/mL
Patient ID Extent of disease at time of draw Days from diagnosis to draw Cycles of chemo prior to draw CK+ CK+ Clusters CK- CK- Clusters Apoptotic PD-L1+ (%)a
B-002 MIBC 4882 2 0.0 0.0 1.1 0.0 0.0 0.0 (0.0)
B-003 MIBC 59 0 0.0 0.0 0.0 0.0 1.8 0.0 (0.0)
B-015 MIBC 58 0 1.0 0.0 0.0 0.0 1.5 0.0 (0.0)
B-018 MIBC 150 4b 0.0 0.0 0.0 0.0 0.0 0.0 (0.0)
B-001 mBCa 55 0 3.3 0.0 2.5 0.0 0.0 0.0 (0.0)
B-004 mBCa 553 4b 0.0 0.0 5.0 0.0 0.0 0.0 (0.0)
B-005 mBCa 225 4b 34.7 0.3 0.7 0.0 12.5 0.3 (0.9)
B-006 mBCa 27 0 7.6 1.5 1.5 0.0 0.0 0.0 (0.0)
B-007 mBCa 162 0 0.0 0.0 0.8 0.0 1.7 0.0 (0.0)
B-010 mBCa 1513 9 1.5 0.0 3.7 0.0 0.0 0.7 (14.3)
B-011 mBCa 633 0 153.2 6.4 2002.1 38.3 0.0 972.3 (44.2)
B-012 mBCa 4606 1 5.5 0.0 5.2 0.0 6.7 0.6 (5.7)
B-013 mBCa 423 5b 0.0 0.0 0.0 0.0 0.0 0.0 (0.0)
B-014 mBCa 43 2b 0.0 0.0 3.3 0.0 1.6 0.0 (0.0)
B-016 mBCa 939 4b 11.9 0.6 5.8 1.0 1.0 0.0 (0.0)
B-017 mBCa 109 0 0.0 0.0 0.0 0.0 0.8 0.0 (0.0)
B-019 mBCa 163 4b 0.0 0.6 1.3 0.0 0.0 1.3 (66.7)
B-020 mBCa 815 8b 4.2 0.0 0.0 0.8 1.7 0.0 (0.0)
B-022 mBCa 7119 20b 4.3 0.0 22.9 0.0 5.7 12.9 (47.4)
B-023 mBCa 444 5 0.0 0.0 0.0 0.0 0.0 0.0 (0.0)
B-025 mBCa 1659 0 76.6 4.3 2.1 0.0 1.1 1.1 (1.3)
B-026 mBCa 724 5b 4.2 0.0 0.0 0.0 2.1 0.0 (0.0)
B-027 mBCa 271 4b 0 0 0 0 0 0.0 (0.0)
B-028 mBCa 247 0 0.9 0 0 0 1.8 0.0 (0.0)
B-029 mBCa 996 0 0 0 0 0 0 0.0 (0.0)
  1. a Includes CK+ and CKCTCs
  2. b indicates patient received at least one cisplatin regimen